I like TARA and ABUS, although ABUS is pivoting to being a patent troll (which I agree with and have paired with ROIV). Truly have to investigate what management is doing, as you illustrated.
My understanding is that ABUS are going to cut costs, sell off their remaining assets (HEP B program, if I recall) & exclusively be a shell w/ a claim on the litigation of intellectual property claim against MRNA & PFE. Worth reading the last few K's.
I think CRGX is an interesting one to discuss in this context. Feels like either it is a great buy here or an argument against your thesis, since it is still trading at significantly negative EV after announcing plans to wind down.
TNFA pharmaceutical. Is another company that’s burning thru cash on a supposedly autoimmune drug that’s been in phase 2 for over two years. The question is whether management is dragging this out for their own personal benefit? Down 87% in the last year.
RGNX is another one worth a look with a flurry of positive news lately, a negative EV, and a tanking stock price
Need ten more Kevin Tang's in the biotech sector...
I like TARA and ABUS, although ABUS is pivoting to being a patent troll (which I agree with and have paired with ROIV). Truly have to investigate what management is doing, as you illustrated.
My understanding is that ABUS are going to cut costs, sell off their remaining assets (HEP B program, if I recall) & exclusively be a shell w/ a claim on the litigation of intellectual property claim against MRNA & PFE. Worth reading the last few K's.
ARVN is another one with negative EV and cash on b/s.
I think CRGX is an interesting one to discuss in this context. Feels like either it is a great buy here or an argument against your thesis, since it is still trading at significantly negative EV after announcing plans to wind down.
One risk which we have as shareholders is the adoption of poison pills. I still can't understand how this is allowed so easily in the USA.
TNFA pharmaceutical. Is another company that’s burning thru cash on a supposedly autoimmune drug that’s been in phase 2 for over two years. The question is whether management is dragging this out for their own personal benefit? Down 87% in the last year.